![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
IY Hwang and AA Elfarra
Department of Comperative Biosciences and Environmental Toxicology Center, University of Wisconsin, Madison.
Recently, we have reported that S-(6-purinyl)-L-cysteine (PC) is a kidney-selective prodrug of 6-mercaptopurine. In the present study, the in vivo metabolism of PC and the biochemical basis of its renal selectivity were further investigated. In addition, several PC analogs were synthesized and evaluated as prodrugs of 6-mercaptopurine by determining the concentrations of 6-mercaptopurine and its metabolites, 6-methylmercaptopurine and 6-thiouric acid, in urine after rats were given the analogs. At 30 min after PC treatments, kidney metabolite concentrations were dependent on the PC dose at 40 to 130 mumol/kg and were not increased when a 400 mumol PC/kg dose was given. At the 400 mumol PC/kg dose, metabolite concentrations in the kidneys were higher at 30 min than at 1 or 3 hr, and were nearly 2.5- and 100-fold higher than those in liver and plasma, respectively. Rates of PC in vitro metabolism by liver and kidney cytosolic cysteine conjugate beta-lyases (beta-lyases) were similar, but metabolism by renal mitochondrial beta- lyase occurred at a 3-fold higher rate than the rate obtained with hepatic mitochondrial beta-lyase. When rats were given aminooxyacetic acid (500 mumol/kg) or probenecid (270 mumol/kg) before PC (130 mumol/kg), total kidney metabolite concentrations were reduced by 55 and 36%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  M. Rooseboom, J. N. M. Commandeur, and N. P. E. Vermeulen Enzyme-Catalyzed Activation of Anticancer Prodrugs Pharmacol. Rev., March 1, 2004; 56(1): 53 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gunnarsdottir, M. Rucki, and A. A. Elfarra Novel Glutathione-Dependent Thiopurine Prodrugs: Evidence for Enhanced Cytotoxicity in Tumor Cells and for Decreased Bone Marrow Toxicity in Mice J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 77 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. M. Commandeur, I. Andreadou, M. Rooseboom, M. Out, L. J. de Leur, E. Groot, and N. P. E. Vermeulen Bioactivation of Selenocysteine Se-Conjugates by a Highly Purified Rat Renal Cysteine Conjugate beta -Lyase/Glutamine Transaminase K J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 753 - 761. [Abstract] [Full Text]
|
|
|
|
|
|
S. Gunnarsdottir and A. A. Elfarra Glutathione-Dependent Metabolism of cis-3-(9H-Purin-6-ylthio)acrylic Acid to Yield the Chemotherapeutic Drug 6-Mercaptopurine: Evidence for Two Distinct Mechanisms in Rats J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 950 - 957. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
